The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Conditions

• Non Small Cell Lung Cancer
• EGFR Gene Mutation
• Non Small Cell Lung Cancer Stage IIIA
• Non-small Cell Lung Cancer Stage IV

Interventions

• DRUG: Furmonertinib

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University